In a study of circulating tumor cells (CTCs) in metastatic genitourinary cancer patients, shorter survival was associated with high CTC counts at baseline and on therapy, specific CTC morphologic subtypes, PD-L1-positive CTCs, and low percent CD4 and percent CD8 T-cells. Heather Chalfin, MD, discusses the data and explains how CTCs may offer an advantage over other forms of liquid biopsy.
Advances in robotic URS will help target stones and reduce ionizing radiation.
In this video, J. Christian Winters, MD, offers advice to young urologists interested in pursuing a career in health care administration, and also why he feels urologists are suited to these roles.
Jonathan Rubenstein, MD, and Mark Painter address the coding question: My local hospital tells me that starting Jan. 1, 2020, I have to consult a Clinical Decision Support Mechanism due to the Appropriate Use Criteria program. I thought that didn’t start until 2021. Can you help?
"The mean and median MIPS final composite scores among urologists in 2017 were 79.3 and 91.2, respectively; this was slightly higher than all specialties combined," writes Robert A. Dowling, MD.
Researchers studying a novel multimodal analgesia protocol at multiple institutions in the U.S. for patients having penile implant surgery found narcotic prescriptions before, during, and in the post-surgery recovery period fell from as high as 50 to 60 narcotic pills to 10 to 15 pills.
Two pharmaceuticals in late-stage development may offer new therapeutic options for patients with rare forms of hyperoxaluria.
The FDA has granted accelerated approval to enfortumab vedotin-ejfv (PADCEV) for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before or after surgery or in a locally advanced or metastatic setting.
The FDA has approved the anti-PD-1 therapy pembrolizumab (KEYTRUDA) as monotherapy for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, nonmuscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
I wanted to take this opportunity to say thank you to all who have read my “Coding and Reimbursement” and “Coding Q&A” articles for the past 23 years.